|
|
|
|
| LEADER |
00000pam a22000004a 4500 |
| 001 |
5872452 |
| 003 |
ICU |
| 005 |
20061211145400.0 |
| 008 |
050614s2006 njua b 001 0 eng |
| 010 |
|
|
|a 2005017065
|
| 020 |
|
|
|a 1588295648 (alk. paper)
|
| 040 |
|
|
|a DLC
|c DLC
|d DLC
|d NhCcYBP
|d UtOrBLW
|d OrLoB-B
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RC271.I45
|b I466 2006
|
| 082 |
0 |
0 |
|a 616.99/4061
|2 22
|
| 245 |
0 |
0 |
|a Immunotherapy of cancer /
|c edited by Mary L. Disis.
|
| 260 |
|
|
|a Totowa, N.J. :
|b Humana Press,
|c c2006.
|
| 300 |
|
|
|a xii, 516 p. :
|b ill. ;
|c 26 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 440 |
|
0 |
|a Cancer drug discovery and development
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g 1.
|t Discovery of target molecules for cancer immunotherapy by genetic and bioinformatic approaches /
|r Ozlem Tureci, Thorsten Klamp, Michael Koslowski, Sebastian Kreiter and Ugur Sahin --
|g 2.
|t Current strategies for the identification of immunogenic epitopes of tumor antigens /
|r Ludmila Muller, Stephanie McArdle, Evelyna Derhovanessian, Thomas Flad, Ashley Knights, Robert Rees and Graham Pawelec --
|g 3.
|t Current and future role of natural-killer cells in cancer immunotherapy /
|r Lisa M. Harlan and Julie Y. Djeu --
|g 4.
|t The role of immune monitoring in evaluating cancer immunotherapy /
|r Holden T. Maecker --
|g 5.
|t Statistical analysis of immune response assays in cancer immunotherapy trials /
|r Susan Groshen --
|g 6.
|t DNA vaccines for cancer immunotherapy /
|r Heesun Kwak and Howard L. Kaufman --
|g 7.
|t Dendritic cells /
|r Weiping Zou and Tyler J. Curiel --
|g 8.
|t Different approaches to dendritic cell-based cancer immunotherapy /
|r Noweeda Mirza and Dmitry Gabrilovich --
|g 9.
|t Anti-idiotype antibody vaccines for the immunotherapy of cancer /
|r Malaya Bhattacharya-Chatterjee, Nitin Rohatgi, Sunil K. Chatterjee, Asim Saha, Rakesh Shukla and Kenneth A. Foon --
|g 10.
|t Autologous tumor-derived heat shock protein vaccine as a new paradigm for individualized cancer therapeutics /
|r Jie Dai and Zihai Li --
|g 11.
|t Tumor-reactive t-cells for adoptive immunotherapy /
|r Helga Bernhard, Julia Neudorfer, Kerstin Gebhard, Heinke Conrad, Dirk H. Busch and Christian Peschel --
|g 12.
|t T-cell adoptive immunotherapy of cancer : from translational models to clinical significance /
|r Peter A. Cohen, Mohamed Awad and Suyu Shu --
|g 13.
|t Retroviral-mediated gene transfer for engineering tumor-reactive t-cells /
|r Jeffrey J. Roszkowski and Michael I. Nishimura --
|g 14.
|t Harnessing the potential of graft-vs-tumor /
|r Nancy H. Hardy and Michael R. Bishop --
|g 15.
|t Tumor-induced immune suppression and immune escape : mechanisms and impact on the outcome of immunotherapy of malignant disease /
|r Michael Campoli and Soldano Ferrone --
|g 16.
|t The tumor microenvironment : regulation of antitumor immunity and implications for immunotherapy /
|r George Coukos and Jose-Ramon Conejo-Garcia --
|g 17.
|t Manipulation of lymphocyte homeostasis for enhancing antitumor immunity /
|r Eduardo Davila and Esteban Celis --
|g 18.
|t Fast-lane evolution in the tumor microenvironment /
|r Gabriella Marincola and Francesco M. Marincola --
|g 19.
|t Manipulating immunological checkpoints to maximize antitumor immunity /
|r Leisha A. Emens, R. Todd Reilly and Elizabeth M. Jaffee --
|g 20.
|t Interleukin-2 as cancer therapy /
|r Joseph I. Clark and Kim A. Margolin --
|g 21.
|t Biological and clinical properties of the type 1 interferons /
|r Douglas W. Leaman, Shaun Rosebeck and Ernest C. Borden --
|g 22.
|t Promising [gamma]-chain cytokines for cancer immunotherapy : interleukins-7, -15, and -21 as vaccine adjuvants, growth factors and immunorestoratives /
|r Terry J. Fry and Crystal L. Mackall --
|g 23.
|t The therapeutic use of natural-killer cells in hematological malignancies /
|r Sherif S. Farag and Michael A. Caligiuri --
|g 24.
|t Antibody therapy for solid tumors /
|r Cristina I. Truica, Dorinda Rouch and Carlos L. Arteaga --
|g 25.
|t Antibody therapy for non-Hodgkin's lymphoma /
|r Stephen M. Ansell and Thomas E. Witzig --
|g 26.
|t Approaches to in vivo imaging of cancer immunotherapy /
|r George A. Vielhauer, Bond Almand, Mary L. Disis, David A. Mankoff and Keith L. Knutson --
|g 27.
|t Design issues for early-stage clinical trials for cancer vaccines /
|r Gina R. Petroni --
|g 28.
|t Monoclonal antibody therapy of cancer /
|r Hossein Borghaei, Matthew K. Robinson and Louis M. Weiner.
|
| 650 |
|
0 |
|a Cancer
|x Immunotherapy.
|0 http://id.loc.gov/authorities/subjects/sh87002642
|
| 650 |
|
0 |
|a Antineoplastic agents
|x Design.
|
| 650 |
|
7 |
|a Antineoplastic agents
|x Design.
|2 fast
|0 http://id.worldcat.org/fast/fst00810598
|
| 650 |
|
7 |
|a Cancer
|x Immunotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00845386
|
| 700 |
1 |
|
|a Disis, Mary L.
|0 http://id.loc.gov/authorities/names/n2005043471
|1 http://viaf.org/viaf/47049122
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 903 |
|
|
|a Hathi
|
| 035 |
|
|
|a (OCoLC)60651107
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i fd066b1e-7aef-5166-bffd-1eca47f48625
|s 0c55860a-7dcf-54ec-9a22-858844cfdff2
|
| 928 |
|
|
|t Library of Congress classification
|a RC271.I45 I466 2006
|l JCL
|c JCL-Sci
|i 6526920
|
| 927 |
|
|
|t Library of Congress classification
|a RC271.I45 I466 2006
|l JCL
|c JCL-Sci
|e BELL
|e CRERAR
|b 75089326
|i 7972749
|
